Concordance of DMET Plus Genotyping Results With Those of Orthogonal Genotyping Methods

There are several hurdles to the clinical implementation of pharmacogenetics. One approach is to employ pre‐prescription genotyping, involving interrogation of multiple pharmacogenetic variants using a high‐throughput platform. We compared the performance of the Drug Metabolizing Enzymes and Transporters (DMET) Plus array (1,931 variants in 225 genes) with that of orthogonal genotyping methods in 220 pediatric patients. A total of 1,692 variants had call rates >98% and were in Hardy–Weinberg equilibrium. Of these, 259 were genotyped by at least one independent method, and a total of 19,942 single‐nucleotide polymorphism (SNP)–patient sample pairs were evaluated. The concordance rate was 99.9%, with only 28 genotype discordances observed. For the genes deemed most likely to be clinically relevant (TPMT, CYP2D6, CYP2C19, CYP2C9, VKORC1, DPYD, UGT1A1, and SLCO1B1), a total of 3,799 SNP–patient sample pairs were evaluable and had a concordance rate of 99.96%. We conclude that the DMET Plus array performs well with primary patient samples, with the results in good concordance with those of several lower‐throughput genotyping methods.

[1]  M. Shapero,et al.  DMET microarray technology for pharmacogenomics-based personalized medicine. , 2010, Methods in molecular biology.

[2]  M. Relling,et al.  A PAI-1 (SERPINE1) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia: a report from the Children's Oncology Group. , 2008, Blood.

[3]  M. Relling,et al.  CRHR1 polymorphisms predict bone density in survivors of acute lymphoblastic leukemia. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Howard L McLeod,et al.  Pharmacogenomics--drug disposition, drug targets, and side effects. , 2003, The New England journal of medicine.

[5]  M. Relling,et al.  A PAI-1 ( SERPINE 1 ) polymorphism predicts osteonecrosis in children with acute lymphoblastic leukemia : a report from the Children ’ s Oncology Group , 2008 .

[6]  S. Steinberg,et al.  A pharmacogenetic study of docetaxel and thalidomide in patients with castration-resistant prostate cancer using the DMET genotyping platform , 2010, The Pharmacogenomics Journal.

[7]  Mark W Farmen,et al.  Multiplex assay for comprehensive genotyping of genes involved in drug metabolism, excretion, and transport. , 2007, Clinical chemistry.

[8]  K. Gunderson,et al.  High-throughput SNP genotyping on universal bead arrays. , 2005, Mutation research.

[9]  Ching-Hon Pui,et al.  Germline genomic variants associated with childhood acute lymphoblastic leukemia , 2009, Nature Genetics.

[10]  M. Loh,et al.  Ancestry and pharmacogenomics of relapse in acute lymphoblastic leukemia , 2011, Nature Genetics.

[11]  T. Ishikawa,et al.  Genetic polymorphisms of ATP-binding cassette transporters ABCB1 and ABCG2: therapeutic implications , 2005, Expert opinion on pharmacotherapy.

[12]  John Deeken,et al.  The Affymetrix DMET platform and pharmacogenetics in drug development. , 2009, Current opinion in molecular therapeutics.

[13]  S. Gabriel,et al.  Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. , 2004, Human molecular genetics.

[14]  P. Hardenbol,et al.  Comprehensive assessment of metabolic enzyme and transporter genes using the Affymetrix Targeted Genotyping System. , 2007, Pharmacogenomics.

[15]  B. Meshkin,et al.  Pharmacogenetic testing: proofs of principle and pharmacoeconomic implications. , 2005, Mutation research.

[16]  T. Klein,et al.  CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network , 2011, Clinical pharmacology and therapeutics.

[17]  D. Venzon,et al.  Clinical pharmacology and pharmacogenetics in a genomics era: the DMET platform. , 2010, Pharmacogenomics.

[18]  B K Tang,et al.  Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. , 1998, Pharmacogenetics.